Gilead Sciences signs joint procurement agreement with European Commission for remdesivir (Veklury) for the treatment of COVID-19 in adult and adolescent patients with pneumonia requiring supplemental oxygen

Agreement enables participating countries in EU and European Economic Area and UK to purchase remdesivir for both real-time demand and stockpiling needs, coordinated by European Commission. It covers purchases over the next six months and has the option to be extended.

Source:

Biospace Inc.